The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD ...

Apogee plans to take a combination approach to AD by targeting Types 1-3 inflammation potentially offering JAK-like inhibition without their ...

Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month ...

A drug already used in the treatment of severe asthma could help treat exacerbations in asthma and COPD, a UK trial has found ...

An injection of a drug already on the market, Benralizamab, promises to be the next revolution in the treatment of asthma ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease ...

A look at some of the health news and happenings from over the weekend Labour makes pre-election promise to build Dunedin ...